Organon & Co | OGN - Debt


Organon & Co reported $8.57B in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Celltrion KRW 160.58B 733.3M Mar/2026
Cspc Pharmaceutical CNY 495M 12.33M Jun/2025
Deva Holding AS TRY 5.3B 871.93M Sep/2023
Dianthus Therapeutics USD 1.36M 79K Mar/2026
Divis Laboratories Ltd INR 40M 40M Mar/2025
Gilead Sciences USD 24.94B 5M Dec/2025
Glaxosmithkline GBP 19.06B 1.31B Mar/2026
Kangmei Pharma CNY 173.71M 42.08M Mar/2026
Knight Therapeutics CAD 77.91M 28.33M Dec/2025
Laboratorios Farma EUR 129.3M 14.89M Jun/2025
Malin Corporation EUR 100K 0 Dec/2023
Medical Developments International AUD 1.99M 152K Jun/2025
Merck USD 49.34B 7.97B Dec/2025
Neuren Pharmaceuticals AUD 0 0 Dec/2024
Novartis USD 47B 14.98B Mar/2026
Organigram Holdings CAD 8.2M 554K Mar/2026
Organon & Co USD 8.57B 75M Mar/2026
Ovoca Bio EUR 0 0 Jun/2021
Pharma Mar EUR 47.54M 1.88M Mar/2026
Qiagen NV USD 1.81B 314.82M Dec/2025
Sartorius EUR 4.28B 372.9M Dec/2025
Sino Biopharmaceutical CNY 9.71B 33.98M Dec/2024
Tilray USD 640.95M 35.17M Jun/2022